E. Spina

Publications278
h-index55
Citations9,841
Highly Influential Citations386
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. de Leon
  • 217 Publications, 5,595 Citations
  • L. Bertilsson
  • 389 Publications, 24,078 Citations
  • A. Serretti
  • 802 Publications, 25,015 Citations
  • G. Trifirò
  • 290 Publications, 5,430 Citations
  • Publications
  • Influence
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
Our objective was to determine the influence of cytochrome P450 (CYP) 2C9 and CYP2C19 genetic polymorphisms on warfarin dose requirement and metabolic clearance.
  • 346
  • 17
Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
The polymorphic cytochrome P450 isoenzymes (CYPs) 2C9, 2C19 and 2D6 metabolise many important drugs, as well as other xenobiotics. Their polymorphism gives rise to important interindividual and… Expand
  • 206
  • 17
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.
BACKGROUND The second-generation antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other compounds with different… Expand
  • 315
  • 15
Metabolic drug interactions with newer antipsychotics: a comparative review.
Newer antipsychotics introduced in clinical practice in recent years include clozapine, risperidone, olanzapine, quetiapine, sertindole, ziprasidone, aripiprazole and amisulpride. These agents are… Expand
  • 233
  • 13
  • PDF
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
Abstract The role of the polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of risperidone to its major active metabolite, 9-hydroxyrisperidone (9-OH-risperidone), has been documented after… Expand
  • 174
  • 12
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
AIMS CYP2C9 is a major enzyme in human drug metabolism and the polymorphism observed in the corresponding gene may affect the therapeutic outcome during treatment with several drugs. The distribution… Expand
  • 214
  • 10
CYP2D6 and CYP2C19 genotype‐based dose recommendations for antidepressants:
a first step towards subpopulation‐specific dosages
Objective: This review aimed to provide distinct dose recommendations for antidepressants based on the genotypes of cytochrome P450 enzymes CYP2D6 and CYP2C19. This approach may be a useful… Expand
  • 406
  • 9
Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs
Summary: As antiepileptic drugs (AEDs) and psychotropic agents are increasingly used in combination, the possibility of pharmacokinetic interactions between these compounds is relatively common. Most… Expand
  • 117
  • 8
Clinical Pharmacokinetics of Fluvoxamine
SummaryFluvoxamine is a selective inhibitor of serotonin reuptake that is widely used in the management of depression.Following oral administration, the drug is absorbed efficiently from the… Expand
  • 76
  • 8
Clobazam Therapeutic Drug Monitoring: A Comprehensive Review of the Literature With Proposals to Improve Future Studies
Background:Clobazam was recently approved for Lennox–Gastaut syndrome in the United States. There is no published review article focused on clobazam therapeutic drug monitoring (TDM) in English.… Expand
  • 56
  • 8